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ABSTRACT: The protein kinase PfCLK3 plays a critical role in
the regulation of malarial parasite RNA splicing and is essential for
the survival of blood stage Plasmodium falciparum. We recently
validated PfCLK3 as a drug target in malaria that offers
prophylactic, transmission blocking, and curative potential. Herein,
we describe the synthesis of our initial hit TCMDC-135051 (1)
and efforts to establish a structure−activity relationship with a 7-
azaindole-based series. A total of 14 analogues were assessed in a
time-resolved fluorescence energy transfer assay against the full-
length recombinant protein kinase PfCLK3, and 11 analogues were further assessed in asexual 3D7 (chloroquine-sensitive) strains of
P. falciparum parasites. SAR relating to rings A and B was established. These data together with analysis of activity against parasites
collected from patients in the field suggest that TCMDC-135051 (1) is a promising lead compound for the development of new
antimalarials with a novel mechanism of action targeting PfCLK3.
■ INTRODUCTION
In the global fight against malaria, the distribution of over 0.5
billion insecticide impregnated bed nets since 2015, together
with artemisinin-based combination therapies, has contributed
to 20 million fewer cases of malaria being reported in 2017
compared to 2010.1 Despite this success, the rate of reduction
in malaria has stalled with no significant reduction seen over
the last 3 years.1 This, together with evidence of the emergence
of resistance to both artemisinin2,3 and partner drugs including
piperaquine and mefloquine,4,5 means that there is a danger
that the progress made in the reduction of malaria will be
reversed unless new medicines with novel mechanisms of
action are discovered. To address this, we have been testing the
notion that targeting malaria parasite protein kinases, known to
be essential for the survival of the parasite, might offer a novel
strategy for the development of next-generation antimalar-
ials.6,7
In 2011, we determined that 36 of the 65 eukaryotic protein
kinases are essential for the survival of the blood stage of the
most virulent species of human malaria, Plasmodium
falciparum.8 Among these protein kinases was PfCLK3
(PF3D7_1114700), one of the four members of the cyclin-
dependent like protein kinase family (PfCLK1-4). The
plasmodium CLK-family are closely related to the mammalian
CLK family and the serine−arginine-rich protein kinase
(SRPK) family,9 both of which are crucial mediators of
multiple phosphorylation events on splicing factors necessary
for the correct assembly and catalytic activity of spliceo-
somes.10 In vitro studies showed that PfCLK3 can phosphor-
ylate parasite SR proteins,11 indicating that PfCLK3, together
with other members of the PfCLK family,12 plays a role in the
processing of parasite RNA.7 We reasoned therefore that
inhibitors of PfCLK3 might have parasiticidal activity at any
stage of the parasite life cycle where RNA splicing played an
essential role.
Screening of ∼25,000 compounds, including all 13,533
compounds of the Tres cantos antimalarial set, resulted in the
discovery of TCMDC-135051 (1, Figure 1), a compound with
nanomolar (nM) activity against PfCLK3 in vitro kinase assays
and submicromolar (μM) parasiticidal activity in asexual blood
stage P. falciparum parasites (Figure 1).13 Subsequent studies
revealed that TCMDC-135051 rapidly killed P. falciparum at
the trophozoite to schizont stages as well as preventing the
development of stage V gametocytes and inhibiting the
development of liver stage parasites. TCMDC-135051 also
showed equivalent in vitro kinase activity at CLK3 from P.
falciparum, Plasmodium berghei (mouse malaria), Plasmodium
vivax (human malaria), and Plasmodium knowlesi (monkey and
human malaria).13 Our recent studies have therefore validated
PfCLK3 as a target with the potential to deliver a curative
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treatment, be transmission blocking, and act as a prophylactic
target.13
Key structural features of 1 include a core 7-azaindole
scaffold with aromatic rings in the 2- and 4-positions (ring A
and B, respectively). These aromatic rings are further
substituted with various functional groups, including a tertiary
amine (ring A) and carboxylic acid (ring B), resulting in a
zwitterionic compound at physiological pH.
7-Azaindoles are a widely studied pharmacophore incorpo-
rated into several therapeutic agents.14 Kinases are the
predominate target with the 7-azaindole moiety generally
interacting at the ATP binding site within the kinase hinge
region.15,16 An interaction occurs between the kinase hinge
region peptide backbone and the azaindole via two H-bonds;
the first involving the pyridine nitrogen lone pair and peptide
backbone NH, and the second between the pyrrole NH and
peptide backbone carbonyl. The resulting H-bond acceptor
and donor bidentate 7-azaindole interaction with the hinge
region of the kinase can occur in the more common “normal”
orientation or the “flipped” orientation with the 2-position of
the 7-azaindole projected out of the hinge region into the
solvent-exposed space.17,18
A number of small molecule kinase 7-azaindole inhibitors
have progressed to different stages of clinical trials.19 A
potential drug candidate GSK1070916 is being developed as
an aurora kinase (Ser/Thr protein kinases family) inhibitor
and has reached human clinical trials (Figure 2A).20 The core
scaffold is a 7-azaindole with aromatic substituents in the 2-
and 4-positions. An X-ray crystal structure of the molecule:-
aurora kinase complex revealed a flipped hinge region binding
mechanism, with 2-aryl projecting out of the hinge region into
solvent and 4-aryl bound within the ribose pocket.20
Substructure analysis using Scifinder revealed several 7-
azaindole analogues described as antimalarials. In 1972,
Verbiscar reported the first example of a 7-azaindole with
antimalarial activity.21 1-p-Chlorobenzyl-7-azaindole-3-α-piper-
idylmethanol displayed antimalarial activity in mice against P.
berghei(Figure 2B). More recently, Picard et al. reported 7-
azaindole compounds that were identified from an in silico
structure-based drug screen (1,013,483 compounds, Chem-
bridge library).22 Compound IND31119 (Figure 2C) binds to
the recombinant N-terminal domain of PfHsp90 and shows
selectivity over human Hsp90 and PfHsp90 mutants.22
In addition to antimalarial activity, the 7-azaindole scaffold
has been identified as having a wide variety of biological
applications, including antitumor activity, and acts as an HIV-1
inhibitor in infected patients.23,24 The 7-azaindole motif can be
regarded as a privileged scaffold in medicinal chemistry as it is
found in three clinical candidates (vemurafenib, PLX3397, and
AZD5363) (Figure 2D), which suggests its usefulness for
developing novel pharmaceuticals.25−27
To investigate the structure−activity relationship (SAR) of
hit compound 1, a series of analogues were prepared through
varying different substituents on ring A and ring B (Figure 1).
The N-diethyl amine group (ring A) was initially replaced with
different amine substituents to investigate lipophilicity and
solubility (Figure 1, SAR1). Next, we replaced the methoxy
moiety (ring A) with hydroxyl or hydrogen to modify polarity
and to explore the role of the methoxy group on activity
(Figure 1, SAR2). The isopropyl substituent (ring B) was
replaced with other small hydrophobic substituents to probe
noncoplanar conformations that could potentially lower the
energy of crystal packing and consequently improve aqueous
solubility and log P (Figure 1, SAR3). Finally, we exchanged
the carboxylic acid group (ring B) with other substituents to
investigate its role in binding, to potentially improve metabolic
stability, and to explore the effect of increased lipophilic
character (Figure 1, SAR4).
Figure 1. Structure and biological profile of hit PfCLK3 inhibitor
TCMDC-135051, 1.
Figure 2. (A) Aurora kinase inhibitor GSK1070916, (B) 1-p-chlorobenzyl-7-azaindole-3-α-piperidylmethanol has in vivo activity against P. berghei,
(C) PfHsp90 inhibitor IND31119, and (D) drug candidates incorporating a core 7-azaindole scaffold, vemurafenib, PLX3397, and AZD5363.
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TCMDC-135051 is a promising hit compound for a
medicinal chemistry program to develop as a preclinical lead
that meets many of the criteria set by the Medicines for
Malaria Venture (capable of rapidly clearing the parasite, has
multistage potency, and killing multiple parasite species with
action as a transmission blocker).28,29 Here, we describe the
synthetic route to TCMDC-135051 and determine a SAR that
will be key for lead development.
Chemistry. To investigate the effect of the N-diethyl group
of ring A on antimalarial activity, analogues of 4-(2-(5-
((diethylamino)methyl)-2-methoxyphenyl)-1H-pyrrolo[2,3-
b]pyridin-4-yl)-2-isopropylbenzoic acid (TCMDC-135051) 1,
8a−c were prepared, as shown in Scheme 1. Protection of 4-
bromo-7-azaindole 2 was achieved using p-toluenesulfonyl
chloride under basic conditions to provide N-tosyl-7-azaindole
3. Regioselective iodination of 3 using lithium diisopropyla-
mide (LDA) and iodine in tetrahydrofuran (THF) at −78 °C
provided 2-iodoazaindole 4, which was subsequently subjected
to Suzuki coupling with (5-formyl-2-methoxyphenyl)boronic
acid to give 2-aryl substituted azaindole 5. Reductive amination
Scheme 1. Synthesis of TCMDC-135051 1 and Analogues 8a−c & 9a
aReagents and conditions: (i) TsCl, NaH, THF, 0 °C, 2 h; (ii) LDA, I2, THF, −78 °C, 3 h; (iii) (5-formyl-2-methoxyphenyl)boronic acid,
Pd(PPh3)4, Na2CO3, 1,4-dioxane, 110 °C, 12 h; (iv) amine, NaBH(AcO)3, 1,4-dioxane, 20 °C, 12 h; (v) CH3OH, K2CO3, 55 °C, 18 h; (vi) 2-
isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid, Pd(dppf)Cl2·CH2Cl2, Na2CO3, 1,4-dioxane, 110 °C, 0.5 h, MW; and (vii)
SOCl2, CH3CH2OH, reflux, 18 h.
Scheme 2. Synthesis of 4-(2-(5-(Aminomethyl)-2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-2-isopropylbenzoic Acid
12a
aReagents and conditions: (i) 4-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile, Pd(PPh3)4, Na2CO3, 1,4-dioxane, 110 °C, 18
h; (ii) CH3OH, K2CO3, 55 °C, 18 h; (iii) 2-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid, Pd(dppf)Cl2.CH2Cl2, Na2CO3,
1,4-dioxane, 110 °C, 0.5 h, MW; and (iv) CoCl2·6H2O, NaBH4, CH3OH.
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of the aldehyde functionality of 5 was performed with various
amines in the presence of sodium triacetoxyborohydride to
give amines 6a−d in excellent yields. Next, the N-tosyl
protecting group was removed under basic conditions at reflux
for 18 h to yield 7a−d. Finally, the desired analogues 1 and
8a−c were obtained by Suzuki cross-coupling with 2-isopropyl-
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid
(see the Supporting Information for boronate ester synthesis).
Compound 9 was prepared, as described in Scheme 1. The
carboxylic acid of 1 was converted to its corresponding ethyl
ester by refluxing in thionyl chloride and ethanol for 18 h.
The synthetic route outlined in Scheme 1 was modified to
prepare primary amine 12. The first step of this synthetic route
involved coupling 2-iodo-azaindole 4 with the appropriate
boronate ester under Suzuki conditions to yield nitrile 10 in
87% yield (Scheme 2). Tosyl deprotection was then achieved
using K2CO3, followed by a Suzuki coupling at the 4-bromo-
azaindole scaffold with the appropriate pinacol boronate ester.
The crude material was reduced in situ using cobalt(II)
chloride hexahydrate and sodium borohydride to provide the
corresponding amine 12 (Scheme 2).
Similarly, analogue 15 was synthesized via Suzuki coupling
of 4 with 2-methoxyphenyl boronic acid, followed by tosyl
deprotection and Suzuki coupling (Scheme 3).
To investigate the precise role of the methoxy group of ring
A on activity, we prepared analogues 19 and 23 in which the
OMe is replaced by a hydroxy group (19) and OMe is
removed (23) (Scheme 3). The synthetic route toward 19
starts with Suzuki coupling of 4 with methoxymethyl ether
(MOM)-protected boronate ester (see the Supporting
Scheme 3. Synthesis of 2-Isopropyl-4-(2-(2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)benzoic Acid 15, 4-(2-(5-
((Diethylamino)methyl)-2-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-2-isopropylbenzoic Acid 19, 4-(2-(3-
((Diethylamino)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-2-isopropylbenzoic Acid 23 and [4-(2-(3-
((Diethylamino)methyl)-2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-2-isopropylbenzoic Acid] 27a
aReagents and conditions: (i) (2-methoxyphenyl)boronic acid, Pd(PPh3)4, Na2CO3, 1,4-dioxane, 110 °C, 12 h; (ii) CH3OH, K2CO3, 55 °C, 18 h;
(iii) 2-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid, Pd(dppf)Cl2·CH2Cl2, Na2CO3, 1,4-dioxane, 110 °C, 0.5 h, MW; (iv)
4-(methoxymethoxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde or 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde,
Pd(PPh3)4, Na2CO3, 1,4-dioxane, 110 °C, 18 h; (v) Et2NH, NaBH(AcO)3, 1,4-dioxane, rt, 18 h; and (vi) HCl, MeCN/H2O 3:1.
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Information for boronate ester synthesis) to yield 16.
Reductive amination of 16 followed by removal of the tosyl
group gave 18. Finally, 18 was coupled with boronate ester
under Suzuki conditions, and the MOM protecting group was
removed under acidic conditions to provide the desired
analogue 19 in excellent yields. Analogue 23 was synthesized in
four steps using the same methods.
To investigate whether the substitution pattern on ring A is
important for antimalarial activity, we produced analogue 27 in
which the methoxy group is moved from para to the ortho
position relative to the methylene N-diethyl functionality
(Scheme 3).
To investigate the effect of the isopropyl substituent (ring B)
on efficacy, we prepared analogues 28−29, as shown in
Scheme 4. 4-Bromo-7-azaindole 7a was coupled with various
boronate esters under Suzuki conditions to yield the desired 4-
aryl-7-azaindole analogues 28−29.
To investigate the role of the carboxylic acid substituent of
ring B on antimalarial activity, several analogues 30−32 were
synthesized, as depicted in Scheme 4. Synthesis of analogues
30−32 was achieved by Suzuki coupling 7a with various
boronate esters (R2 = 1H-tetrazole or H) to yield target
compounds 30−31 in good yields.
An isomer, in which the isopropyl and carboxylic acids were
switched, 32 was synthesized to investigate the role of these
functional groups on antimalarial activity (Scheme 4).
■ RESULTS AND DISCUSSION
In this work, we have maintained the core 7-azaindole
molecular scaffold of TCMDC-135051 and focused on the
SARs of the substitutes on ring A and -B to assess the
requirement for this functionality. All synthesized analogues
were assessed in a time-resolved fluorescence energy transfer
(TR-FRET) PfCLK3 in vitro kinase assay against the full
recombinant protein kinase (Tables 1 and 2). Analogues which
gave low nanomolar activity were then further assessed in live
parasite viability (parasiticidal) assays using laboratory strain
3D7 (chloroquine-sensitive) P. falciparum (Tables 1 and 2).
The synthesized analogues were evaluated for log D7.4
Scheme 4. Synthesis of 4-Aryl-7-azaindole Analogues, 28−32a
aReagents and conditions: (i) boronate esters, Pd(dppf)Cl2.CH2Cl2, Na2CO3, 1-4-dioxane, 110 °C, 0.5 h, MW.
Table 1. Physicochemical Properties and Activity Data of TCMDC-135051 Ring A Analogues
PfCLK3 3D7
analogue R1 R2 R3 IC50 (nM)
a pIC50 EC50 (nM)
b pEC50 log D7.4
c clint (mL/min/g liver)
d
1 NEt2 OMe H 40 7.4 (±0.221) 180 6.7 (±0.126) 0.93 1.12
8a NMe2 OMe H 29 7.5 (±0.224) 457 6.3 (±0.129) 0.85 2.53
8b N-pyrrolidinyl OMe H 38 7.4 (±0.113) 382 6.4 (±0.081) 2.43 1.94
8c N-morpholinyl OMe H 9 8.0 (±0.191) 1339 5.9 (±0.118) 1.20 1.60
12 NH2 OMe H 76 7.1 (±0.142) 2801 5.6 (±0.104) 0.61 2.92
15 H OMe H 79 7.1 (±0.132) 1456 5.8 (±0.152) 2.45 2.54
19 NEt2 OH H 22 7.7 (±0.115) 3529 5.5 (±0.133) 0.59 1.94
23 NEt2 H H 25 7.6 (±0.089) 309 6.5 (±0.114) 0.80 0.85
27 NEt2 H OMe 17 7.7 (±0.116) 3167 5.6 (±0.109) 0.74 1.65
aIC50 (the concentration of an inhibitor where the response is reduced by half).
bEC50 (the concentration of a drug that gives half-maximal
response). IC50 and EC50 values are means ± SEM of three independent experiments run in triplicates (n = 3).
clog D7.4 (distribution co-efficient)
was estimated using HPLC chromatography. dIn vitro intrinsic clearance in mouse liver microsomes.
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(distribution co-efficient) and metabolic stability, and the
results are shown in Tables 1 and 2.
SAR1 corresponding to analogues 8a−c, 12, and 15 were
designed to examine the effect of the N-diethyl group of ring A
on antimalarial activity. In analogue 8a, the N-diethyl group
was replaced with an N-dimethyl group to investigate the effect
of alkyl group size and molecular lipophilicity (log D7.4 = 0.85).
For in vitro kinase activity of 8a, the half maximal inhibitory
activity (IC50) IC50 = 29 nM (pIC50 = 7.5 ± 0.224) remains
the same in recombinant PfCLK3 kinase, whereas a 2-fold
decrease in the half maximal parasite growth inhibition effect
(EC50) EC50 = 457 nM (pEC50 = 6.3 ± 0.129) was observed
(Table 1). To further investigate the steric requirements of this
functionality and polarity, pyrrolidine (8b) and morpholino
groups (8c) were introduced. Analogue 8b shows comparable
in vitro kinase activity, IC50 = 38 nM (pIC50 = 7.4 ± 0.113),
and a 2-fold decrease in parasite growth inhibition 8b, EC50 =
382 nM (pEC50 = 6.4 ± 0.081), was observed. However, the
more polar 8c shows a slight improvement in vitro kinase
activity of IC50 = 9 nM (pIC50 = 8.0 ± 0.191), a 7-fold
decrease in parasite growth inhibition was observed 8c, EC50 =
1339 nM (pEC50 = 5.9 ± 0.118) (Table 1). To further
investigate the polarity of this moiety, we replaced the N-
diethyl functionality with a more polar primary amine (log D7.4
= 0.61). Analogue 12 incorporating a primary amine gave an
IC50 = 76 nM (pIC50 = 7.1 ± 0.142), thus was 2-fold less
potent in vitro and showed a dramatic loss of efficacy, EC50 =
2801 nM (pEC50 = 5.6 ± 0.104), in parasites, indicating the
need to decrease the polarity of the amine group for optimal
parasite growth inhibition (Table 1). Analogue 15, with the
alkyl amine group removed (log D7.4 = 2.45) was less potent in
vitro, IC50 = 79.0 nM (pIC50 = 7.1 ± 0.132) against
recombinant PfCLK3 protein and in parasites, EC50 = 1456
nM (pEC50 = 5.8 ± 0.152). There was a 7-fold drop in the
parasite growth inhibition, suggesting that the alkyl amine on
ring A is important for antimalarial activity (Table 1).
To explore the importance of the methoxy group (OMe) on
ring A, two analogues, hydroxyl 19 and 23, with methoxy
removed, were prepared. We first replaced the OMe group
with a hydroxyl to investigate the role of polarity on activity
(log D7.4 = 0.59). Next, we replaced the OMe group with
hydrogen (23) to investigate the importance of this
functionality for activity. For both compounds 19 and 23, in
vitro kinase potency was comparable, IC50 = 22 nM (pIC50 =
7.7 ± 0.115) and IC50 = 25 nM (pIC50 = 7.6 ± 0.089),
respectively (Table 1). When tested in parasites, 19 shows
significant loss of activity, EC50 = 3529 nM (pEC50 = 5.5 ±
0.133). Interestingly, replacing the OMe group with a
hydrogen, 23 also shows a 1.5-fold decrease in potency, EC50
= 309 nM (pEC50 = 6.5 ± 0.114) against parasites. These data
demonstrated that the OMe group on ring A is required for in
vitro kinase and parasite growth inhibition. Overall, analogues
(8a−c, 12, 15, 19, and 23) showed good metabolic stability in
mouse liver microsomes (Table 1).
Next, we turned our attention to study the SAR of various
functional groups on ring B. First, we examined the role of
binding through van der Waals interactions in vitro and
lipophilicity in parasites, imparted by the ring B isopropyl
group, on antimalarial activity. In analogue 28 (log D7.4 =
0.66), the isopropyl group was replaced with methyl, whereas
in analogue 29 (log D7.4 = 0.65), the isopropyl was removed
and replaced with hydrogen. Analogues 28 and 29 had a
modest increase on in vitro kinase activity, IC50 = 24 nM
(pIC50 = 7.6 ± 0.10) and IC50 = 34 nM (pIC50 = 7.5 ± 0.089),
respectively. However, a dramatic loss of potency was observed
for both compounds 28 and 29 with EC50 = 1185 nM (pEC50
= 5.6 ± 0.097) and EC50 = 3272 nM (pEC50 = 5.5 ± 0.124),
respectively, representing a 6-fold and 16-fold decrease in
parasite growth inhibition (Table 2). Therefore, this group is
not required for binding in vitro; however, the effect of
lipophilicity appears to be very important for parasite growth
inhibition. Analogues 28 and 29 were then evaluated for
intrinsic clearance in mouse microsome. Analogue 28 (Clint =
1.33 mL/min/g liver) showed a similar clearance value to that
of 1 (TCMDC-051) in mouse liver microsomes, whereas 29
had a higher clearance under the same conditions (Clint =
11.01 mL/min/g liver) indicating the importance of the
isopropyl group.
At this point, we decided to increase the lipophilicity and
replace the isopropyl group to the larger tert-butyl group.
However, due to a restriction of the chemistry of boronate
esters (instability of tert-butyl anion required for SNAr
Table 2. Physicochemical Properties and Activity Data of TCMDC-135051 Ring B Analogues
PfCLK3 3D7
analogue R1 R2 IC50 (nM)
a pIC50 ED50 (nM)
b pEC50 log D7.4
c Clint (mL/min/g liver)
d
28 CH3 CO2H 24 7.6 (±0.10) 1185 5.6 (±0.097) 0.66 1.33
29 H CO2H 34 7.5 (±0.089) 3272 5.5 (±0.124) 0.65 11.01
30 CH(CH3)2 1H-tetrazole 19 7.7 (±0.089) 270 6.6 (±0.158) 0.93 2.32
31 CH(CH3)2 H 1300 6.0 (±0.091) ND
e NDe 4.45 9.54
9 CH(CH3)2 CO2CH2CH3 390 6.4 (±0.087) ND
e NDe 2.45 16.06
32 CO2H CH(CH3)2 1385 4.9 (±0.093) ND
e NDe NDe NDe
aIC50 (the concentration of an inhibitor where the response is reduced by half).
bEC50 (the concentration of a drug that gives half-maximal
response). IC50 and EC50 values are means ± SEM of three independent experiments run in triplicates (n = 3).
clog D7.4 (distribution co-efficient)
was estimated using HPLC chromatography. dIn vitro intrinsic clearance in mouse liver microsomes. eND, not determined.
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reaction), we could not synthesize the proposed molecule.
From these data, the alkyl substituent on ring B appears not to
be particularly important in the molecular recognition event
with PfCLK3, however is key for overall molecular lipophilicity
that contributes to parasite growth inhibition.
To investigate the requirements (i.e., ionic and H-bonding)
of the carboxylic acid (ring B) for antimalarial activity, we
employed a series of structural changes. The presence of
carboxylic acid functionality in a drug molecule has several
potential drawbacks, including limited permeability across
biological membranes, metabolic instability, and potential
idiosyncratic toxicities. A common isostere of a carboxylic acid,
that overcomes many of these physicochemical limitations, is a
tetrazole. We therefore designed tetrazole analogue 30. This
change was orchestrated to increase the lipophilicity of the
molecule, retain H-bonding capability, and investigate the role
of potential ionic interactions with the enzyme. The tetrazole
analogue 30 shows improved in vitro kinase potency with an
IC50 = 19 nM (pIC50 = 7.7 ± 0.089), with comparable parasite
growth inhibition, EC50 = 270 nM (pEC50 = 6.6 ± 0.158)
(Table 2). The potency of analogue 30 was tested against
resistant mutant PfCLK3 (PfCLK3_G449P) 3D7 parasites.13
The parasiticidal activity of TCMDC-135051 1 against asexual
3D7 parasites was 180 nM (pEC50 = 6.7), and 1806 nM
(pEC50 = 5.74) against mutant G449P. A 15-fold shift in
sensitivity to the inhibitor. The tetrazole 30, with an EC50 =
270 nM (pEC50 = 6.6) in wild type parasites showed a
significant reduction is potency against the mutant G449P
parasites, EC50 = 3494 nM (pEC50 = 5.4). This represents a
13-fold shift in potency.
Analogue 31 where the carboxylic acid group was replaced
with a hydrogen shows significant loss of in vitro kinase activity,
IC50 = 1300 nM (pIC50 = 6.0 ± 0.091). Analogue 31 has high
lipophilicity (log D7.4 = 4.45) and in vitro high intrinsic
clearance (Clint = 9.54 mL/min/g liver) demonstrating the
importance of the carboxylic acid group (Table 2).
Analogue 9 has improved lipophilicity (log D7.4 = 2.45), yet
the in vitro kinase potency was low, IC50 = 390 nM (pIC50 =
6.4 ± 0.087), indicating that the presence of a functional group
capable of donating a hydrogen bond is important for activity
(Table 2). This analogue was not tested in parasites because of
the low potency against recombinant PfCLK3 kinase.
The final part of our SAR assessment was dedicated to
exploring the possibility of orientation of key substituents.
Varying the position of the OMe group from para to the ortho
position 27 resulted in a 2-fold increase in in vitro kinase
activity, IC50 = 17 nM (pIC50 = 7.7 ± 0.116). However, when
27 was tested in parasites, the activity was lowered by 15-fold,
EC50 = 3167 nM (pEC50 = 5.6 ± 0.109) (Table 1).
We next investigated the position of the isopropyl and
carboxylic acid substituents of ring B 32 on antimalarial
activity. The change of orientation of the substituent is
detrimental for the in vitro kinase activity, IC50 = 1385 nM
(pIC50 = 4.9 ± 0.093), and therefore was not tested in
parasites. These data suggested that the positioning of the
isopropyl and carboxylic acid group was essential for binding to
its cellular target.
No X-ray crystal structure has been reported for PfCLK3
and so a homology model of PfCLK3 was created using
SWISS-MODEL to provide evidence of our proposed binding
mechanism (i.e., hinge binder), which we hypothesized based
on other literature examples of 7-azaindole scaffolds binding at
the hinge region of the kinase domain. The structure of the
human PRPF4B kinase domain was selected as the template as
the closest homologue [PDB 6CNH (sequence identity
53.2%)].30 Model accuracy was determined to be reasonable
using SWISS-MODEL with QMEAN (qualitative model
energy analysis) score = −2.26 and GMQE (global model
quality estimation) = 0.77. Overlay with Human Jnk1alpha
kinase with 4-phenyl-7-azaindole IKK2 inhibitor bound (PDB
4AWI) facilitated identification of the proposed binding
pocket.31 Based on this model, we propose that the 7-aza-
indole scaffold interacts with the hinge region in the flipped
conformation, that is, H-bonding to the peptide backbone of
the hinge region (Figure 3). The benzoic acid on ring B
appears to occupy the ribose pocket and interacts with Lys-
394. In the model, the ring B isopropyl group occupies a
hydrophobic back pocket. Ring A projects into the solvent-
exposed space. The diethyl-amine and methoxy substituents
are solvent exposed and may contribute to the orientation of
the 7-azaindole in the flipped binding conformation.
We previously demonstrated that TCMDC-135051 showed
selective inhibition of PfCLK3 when compared against the
closely related human kinases (PRPF4B and CLK2), as well as
the closest parasite kinase (PfCLK1), and other parasite
kinases (PfPKG and PfCDPK1).13 To further assess kinase
selectivity, and the potential for off-target toxicity, TCMDC-
135051 was screened against 140 human kinases at 1 μM
concentration. Only nine kinases were found to have less than
20% activity at this concentration (see the Supporting
Information).
TCMDC-135051 Inhibits the Growth of Clinical Field
Isolates. An important property for next-generation anti-
malarials is effectiveness against parasites that are resistant to
currently used antimalarials. To determine whether the parent
Figure 3. Putative binding mode of TCMDC-135051 1 in a PfCLK3 homology model.
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molecule TCMDC-135051 1 might offer such activity, we
tested the efficacy of this compound against parasites that were
collected from malaria patients in The Gambia. These parasite
strains were sequenced and those that contained genetic
markers of resistance were selected (Table 3). Parasites were
then tested for resistance to pyrimethamine, a frontline
antimalarial where resistance has been documented in parasites
originating from The Gambia (Figure 4A).32
This analysis identified nine parasite isolates from patients
with varying degrees of resistance to pyrimethamine (Figure
4A,B) and which contained mutations in one or more of the
three genes; PfCRT (P. falciparum chloroquine-resistant
transporter gene), PfMDR1 (P. falciparum multidrug-resistant
gene 1), and PfDHFR (P. falciparum dihydrofolate reductase
gene). The mutations identified in these genes (Table 3) have
previously been associated with resistance to commonly used
antimalarials, including chloroquine and pyrimethamine.33 An
EC50 concentration of pyrimethamine was then determined
using the laboratory strain parasite 3D7 (EC50 = 18 nM).
Using this concentration in parasite reduction rate (PRR)
assays, all isolates showed a reduction in parasitemia by at least
70% except for three isolates (GB0020, GB002, and GB0026),
which showed resistance to pyrimethamine treatment. These
three isolates uniquely contained triple mutations in the
PfDHFR gene and a single mutation in PfCRT (Table 3). For
these isolates, resistance was evident after 24 h of treatment
with pyrimethamine where parasitemia was only reduced by
45, 64, and 36%, respectively (Figure 4A). Resistance to
pyrimethamine of these three isolates was still evident after 72
h of drug treatment (Figure 4A) and in parasites exposed to
10× EC50 (180 nM) of pyrimethamine (Figure 4B).
In contrast, all isolates treated with the EC50 of TCMDC-
135051, as determined in 3D7 parasites (EC50 = 180 nM),
demonstrated total susceptibility, including isolates GB0020,
GB002, and GB0026 (Figure 4C). This was true both at the
EC50 concentration and 10× EC50 for TCMDC-135051
(Figure 4D). Hence in the field isolates tested, TCMDC-
135051 showed equivalent activity against parasites that
Table 3. Genotypes of Field Isolated Parasite Strains: Whole Genome Sanger Sequencing Identified Mutations in Three
Parasite Genes (CRT, PfMDR1, and PfDHFR) Associated with Drug Resistancea
PfCRT PfMDR1 PfDHFR
sample ID K76T N86Y Y184F N1042D N51I C59R S108N I164L
GB0006 X X X N X X N L
GB0004 K N Y N N R N L
GB0026 K N X N N R N L
GB002 T N X N I C N L
GB0021 K N F N X X N L
GB0048 X N F N I C N L
GB0071 X N Y N N C N L
GB0087 T N Y N I C N L
GB0020 T Y Y N I C N L
aShown are the amino acid changes associated with each of these three genes and whether the parasite strain contained the mutation.
Figure 4. PRR of clinical isolates comparing pyrimethamine and TCMDC-135051 at EC50 and 10 times the EC50 of each drug. This represent the
average of triplicate.
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carried genetic markers of resistance and those that showed
actual resistance to a frontline antimalarial. This indicates the
possibility that the parent molecule, and potentially analogues
of this molecule, would be active against naturally circulating
malaria parasites harboring mutations that promoted resistance
to current antimalarial drugs. The PRR assay was setup using
clinical isolates previously cryopreserved in liquid nitrogen
(LN2). These were thawed and placed in culture for at least
one cycle (∼48 h ± 2). The life cycle stage of the parasites was
monitored using a blood film, and greater than 95% of the
parasites are expected to egress and form new invading rings.
These new rings, mainly 0−3 h old postinvasion, were used as
time point 0 hours (t = 0) for the assay. The parasites are then
cultured with drugs for 24, 48, and 72 h. For 24 h treatment,
the drug was removed by washing twice with wash media and
for longer treatments (48 and 72 h time points), drug was
replenished with fresh drug every 24 h. After the treatment
period, parasites were grown in fresh media for an additional
48 h in freshly stained erythrocytes to allow invasion from any
viable parasites.
■ CONCLUSIONS
In summary, we report the synthesis of hit PfCLK3 inhibitor
TCMDC-135051 1 (PfCLK3 IC50 = 40 nM, 3D7 EC50 = 180
nM) and a series of related 7-azaindole-based analogues. Of
the 14 analogues, 11 had low nanomolar activity and were
further assessed in live parasite viability assays using the 3D7
(chloroquine-sensitive) strain of P. falciparum. Tetrazole
analogue 30 was identified with improved in vitro kinase
activity (PfCLK3, IC50 = 19 nM) and comparable activity in
parasites 3D7 (EC50 = 271 nM). SAR was established for both
ring A, highlighting the importance of H-bonding functionality
in the 4-aryl position, and for the alkyl amino group on ring B.
Together these data provide a good starting point for the hit to
lead development of novel PfCLK3 inhibitors based on
TCMDC-135051 (1).
■ EXPERIMENTAL SECTION
General Information. Chemicals and solvents were purchased
from standard suppliers and used without additional purification. All
glassware were dried with a flame under flushing argon gas or stored
in the oven and allowed to cool under an inert atmosphere prior to
use. Anhydrous solvents (THF, DCM, and Et2O) were obtained by
passage through solvent filtration systems (Pure Solv), and solvents
were transferred by the syringe. PET ether refers to petroleum (bp
40−60 °C, reagent grade, Fisher Scientific). All reactions were carried
out under a blanket of nitrogen in an inert or dry atmosphere. Thin-
layer chromatography (TLC) was performed using aluminium plates
precoated with silica gel (0.25 mm, 60 A° pore-size) impregnated with
a fluorescent indicator (254 nm). Visualization on TLC was achieved
by the use of UV light (254 nm). Flash column chromatography was
undertaken on silica gel (400−630 mesh). Proton nuclear magnetic
resonance spectra (1H NMR) were recorded on an AVANCE III 400
Bruker (400 MHz). Proton chemical shifts are expressed in parts per
million (ppm, δ scale) and are referenced to residual protium in the
NMR solvent (CDCl3, δ 7.26; CD3OD, δ 3.31 and DMSO-d6, δ 2.50).
The following abbreviations were used to describe peak patterns when
appropriate: br = broad, s = singlet, d = doublet, t = triplet, q =
quadruplet, sept = septet, and m = multiplet. Coupling constants, J,
were reported in hertz unit (Hz). Carbon 13 nuclear magnetic
resonance spectroscopy (13C NMR) was recorded on an AVANCE III
400 Bruker (101 MHz) and was fully decoupled by broad-band
decoupling. Chemical shifts were reported in ppm referenced to the
centerline of a triplet at 77.0, 49.0, and 39.5 ppm of CDCl3, CD3OD,
and DMSO-d6. Low-resolution mass spectrometry was performed on
a Thermo Scientific LCQ Fleet quadrupole mass spectrometer using
electrospray ionization in the positive mode (ESI+), employing a 150
mm × 4 mm C18 column (Dr. Maisch Reprosil Gold). High-
resolution mass spectrometry (HRMS) was performed on a Bruker
microTOF-Q II (ESI+). Preparative high-performance liquid
chromatography (HPLC) was carried out on a Dionex HPLC system
equipped with Dionex P680 pumps and a Dionex UVD170U UV−vis
detector (monitoring at 214 and 280 nm), using a Phenomenex,
Gemini, C18, 5 μm, 250 × 21.2 mm column. Gradients were
performed using solvents consisting of A (H2O + 0.1% TFA) and B
(CH3CN + 0.1% TFA), and fractions were lyophilized on a Christ
Alpha 2-4 LO plus freeze dryer. Final molecules were analyzed on a
Shimadzu reverse-phase HPLC (RP-HPLC) system equipped with
Shimadzu LC-20AT pumps, a SIL-20A autosampler, and a SPD-20A
UV−vis detector (monitoring at 214 nm) using a Phenomenex, Aeris,
5 μm, peptide XB-C18, 150 × 4.6 mm column at a flow rate of 1 mL/
min. RP-HPLC gradients were run using a solvent system consisting
of solution A (5% CH3CN in H2O + 0.1% TFA) and B (5% H2O in
CH3CN + 0.1% TFA). A gradient from 0 to 100% solution B over 20
min was run. Purity of all final compounds is >95%, as determined by
RP-HPLC.
Experimental Procedures and Characterization Data. 4-
Bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridine (3). To a solution of
sodium hydride (1.83 g, 76.1 mmol, 3 equiv) and tetrabutylammo-
nium bromide (0.25 g, 0.76 mmol, 0.03 equiv) in dichloromethane
(80 mL) at 0 °C was added 4-bromo-1H-pyrrolo[2,3-b]pyridine, 2 (5
g, 25.4 mmol, 1 equiv). The mixture was then left to stir at 0 °C for 15
min. Toluene sulfonylchloride (5.81 g, 30.5 mmol, 1.2 equiv) in
dichloromethane (20 mL) was slowly added over 5 min. The mixture
was then left to warm up to room temperature and stirred for 1 h. The
reaction was quenched by addition of water and extracted with
dichloromethane. The organic layer was washed with brine and dried
over magnesium sulfate. The residue was then purified by flash
column chromatography (10% ethyl acetate−PET ether) to give 3 as
a colorless solid (8.83 g, 99%); 1H NMR (400 MHz, CDCl3): δ 8.22
(d, J = 5.2 Hz, 1H), 8.06 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 4.0 Hz, 1H),
7.35 (d, J = 5.3 Hz, 1H), 7.28 (d, J = 8.0 Hz, 2H), 6.64 (d, J = 4.0 Hz,
1H), 2.37 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 146.8, 145.5,
145.0, 135.1, 129.7, 128.2, 127.0, 125.7, 124.4, 122.1, 104.9, 21.7;
HRMS m/z: calcd for C14H11BrN2NaO2S [M + Na]
+, 372.9617;
found, 372.9608 (Δ = 2.3 ppm).
4-Bromo-2-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridine (4). n-Butyl-
lithium (2.5 M; 6.3 mL, 15.6 mmol, 1.1 equiv) was added dropwise
to diisopropylamine (2.4 mL, 17.2 mmol, 1.2 equiv) in diethyl ether
(30 mL) at −78 °C over a period of 5 min. The resulting solution was
stirred at −78 °C for 60 min and then slowly added via cannula to a
solution of 4-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridine, 3 (5.0 g, 14.2
mmol, 1 equiv) and tetramethylethylenediamine (2.3 mL, 15.7 mmol,
1.1 equiv) in diethyl ether (170 mL) over a period of 10 min at −78
°C. The resulting solution was then stirred at −78 °C for 90 min.
Iodine (5.4 g, 21.4 mmol, 1.5 equiv) was added in one portion, and
the reaction mixture was stirred at −78 °C for 60 min. The reaction
was quenched with saturated ammonium chloride solution, and the
organic layer was washed with aqueous sodium thiosulfate and brine
before drying over magnesium sulfate. The residue was then purified
by column chromatography (20% ethyl acetate−PET ether) to give 4
as a colorless solid (5.59 g, 85%; 1H NMR (400 MHz, CDCl3): δ 8.11
(d, J = 5.2 Hz, 1H), 8.01 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 5.2 Hz, 1H),
7.22−7.19 (m, 2H), 6.96 (s, 1H), 2.30 (s, 3H); 13C NMR (101 MHz,
CDCl3): δ 149.1, 145.7, 144.7, 135.4, 129.8, 128.3, 125.3, 123.6,
122.4, 119.4, 21.7; HRMS m/z: calcd for C14H10BrIN2NaO2S [M +
Na]+, 498.8583; found, 498.8602 (Δ = −3.8 ppm).
Method A: General Method of Suzuki Cross-Coupling. To a
solution of desired aryl bromide (1.0 equiv) and tetrakis-
(triphenylphosphine)palladium(0) (0.05 equiv) in 1,4-dioxane was
added boronic acid/ester (1.1 equiv) under a nitrogen atmosphere.
Aqueous sodium carbonate (2 M, 7.0 equiv) was then added, and the
reaction mixture was left to stir at 110 °C for 18 h. Solvent was
removed under vacuum, and the crude was dissolved in ethyl acetate
and poured into water and extracted with ethyl acetate. The organic
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layer was washed with brine before drying over magnesium sulfate and
purified by flash column chromatography as indicated.
Method B: Reductive Amination of Aldehydes. To a solution
of aryl aldehyde (1.0 equiv) in 1,4-dioxane was added amine (1.5
equiv), and the solution was allowed to stir for 2 min before the
addition of sodium triacetoxyborohydride (2.5 equiv). The reaction
mixture was stirred at room temperature for 18 h before quenching
with ammonium hydroxide. The reaction mixture was extracted with
ethyl acetate and washed with brine. The organic layer was dried over
magnesium sulfate, and the residue was purified by flash column
chromatography as indicated.
Method C: Deprotection of Azaindole. To a solution of
protected 7-azaindole (1 equiv) in methanol was added potassium
carbonate (3.5 equiv) and refluxed for 18 h. The reaction was poured
into a mixture of EtOAc (10 mL) and H2O in a separatory funnel.
Solvent was then removed under vacuum, and the residue was then
purified by flash column chromatography as indicated.
Method D: Suzuki Cross-Coupling with Boronate Ester. To a
10 mL microwave vial containing the required bromo-7-azaindole (1
equiv) in 1,4-dioxane was added boronic acid/ester (1.1 equiv),
Pd(dppf)Cl2·DCM complex (0.05 equiv) under a nitrogen atmos-
phere. The solution was purged with nitrogen for 5 min, and the
reaction microwaved at 110 °C for 0.5 h. The reaction was allowed to
cool to room temperature, and the mixture was filtered through Celite
eluting with methanol. The filtrate was evaporated, and the resulting
residue was purified by preparative HPLC: 10−95% acetonitrile in
water + 0.1% TFA to give the desired products.
Method E: Synthesis of Boronate Ester. Boronate esters
required for Suzuki coupling were prepared according to the
procedure reported in the literature.34 To a solution of aryl bromide
(1 equiv), bis(pinacolato)diboron (1.5 equiv) and potassium acetate
(3 equiv) in 1,4-dioxane (20 mL), PdCI2(dppf)·CH2Cl2 complex (0.1
equiv) were added under nitrogen and stirred at 100 °C for 3 h. The
reaction mixture was quenched with saturated NaHCO3 and extracted
with ethyl acetate. The organic phase was dried (Na2SO4), filtered,
and concentrated to dryness. The crude product was purified by
chromatography (20% ethyl acetate−PET ether) to give the desired
boronate esters.
3-[4-Bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-2-yl]-4-methoxy-
benzaldehyde (5). Prepared according to method A. Purification by
flash chromatography (50% ethyl acetate−PET ether) afforded 5 as
yellow oil (1.72 g, 70%); 1H NMR (400 MHz, CDCl3): δ 9.90 (s,
1H), 8.15 (d, J = 5.2 Hz, 1H), 7.95 (dd, J = 8.5, 2.1 Hz, 1H), 7.84 (d,
J = 2.1 Hz, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 5.3 Hz, 1H),
7.13 (d, J = 8.2 Hz, 2H), 7.04 (d, J = 8.5 Hz, 1H), 6.52 (s, 1H), 3.85
(s, 3H), 2.27 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 190.4, 163.5,
148.7, 145.1, 144.8, 137.6, 135.8, 134.4, 131.4, 129.4, 129.4, 128.1,
125.1, 123.3, 123.1, 122.3, 110.6, 107.9, 56.1, 21.6; HRMS m/z: calcd
for C22H17BrN2NaO4S [M + Na]
+, 506.9985; found, 506.9977 (Δ =
1.5 ppm).
N-(3-(4-Bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methox-
ybenzyl)-N-Ethylethanamine (6a). Prepared according to method B.
Purification by flash chromatography (5% methanol−dichloro-
methane) afforded 6a as yellow oil (920 mg, 72%); 1H NMR (400
MHz, CD3OD): δ 8.15 (d, J = 5.3 Hz, 1H), 7.76 (d, J = 8.4 Hz, 2H),
7.65 (dd, J = 8.5, 2.4 Hz, 1H), 7.62 (d, J = 2.3 Hz, 1H), 7.47 (d, J =
5.3 Hz, 1H), 7.31 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.5 Hz, 1H), 6.65
(s, 1H), 4.45−4.35 (m, 2H), 3.81 (s, 3H), 3.31−3.23 (m, 4H), 2.36
(s, 3H), 1.38 (t, J = 7.3 Hz, 7H); 13C NMR (101 MHz, CD3OD): δ
159.3, 148.4, 145.7, 144.3, 138.2, 135.5, 133.7, 133.6, 129.1, 127.6,
124.7, 123.3, 122.3, 122.3, 120.8, 111.1, 107.6, 55.2, 54.9, 20.1;
HRMS m/z: calcd for C26H28BrN3O3S [M + H]
+, 541.1035; found,
542.1093 (Δ = 2.7 ppm).
1-({3-[4-Bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-2-yl]-4-
methoxyphenyl}methyl)-N,N-dimethylamine (6b). Prepared accord-
ing to method B. Purification by flash chromatography (5%
methanol−dichloromethane) afforded 6b as yellow oil (225 mg,
70%); 1H NMR (400 MHz, CD3OD): δ 8.17 (d, J = 5.3 Hz, 1H),
7.78 (d, J = 8.4 Hz, 2H), 7.65 (dd, J = 8.5, 2.3 Hz, 1H), 7.61 (d, J =
2.3 Hz, 1H), 7.50 (d, J = 5.3 Hz, 1H), 7.33 (d, J = 8.0 Hz, 2H), 7.21
(d, J = 8.5 Hz, 1H), 6.66 (s, 1H), 4.27 (d, J = 14.4 Hz, 2H), 3.83 (s,
3H), 2.84 (s, 7H), 2.38 (s, 3H); 13C NMR (101 MHz, CD3OD): δ
156.2, 147.9, 142.1, 137.0, 131.0, 129.6, 129.5, 124.1, 122.6, 119.3,
118.8, 111.5, 98.8, 62.6, 55.0, 43.6; HRMS m/z: calcd for
C24H25BrN3O3S [M + H]
+, 514.0795; found, 514.0790 (Δ = 0.9
ppm).
1-({3-[4-Bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-2-yl]-4
methoxyphenyl}methyl)pyrrolidine (6c). Prepared according to
method B. Purification by flash chromatography (5% methanol−
dichloromethane) afforded 6c as yellow oil (330 mg, 97%); 1H NMR
(400 MHz, CD3OD): δ 8.13 (d, J = 5.2 Hz, 1H), 7.77 (d, J = 8.4 Hz,
2H), 7.65−7.67 (m, 2H), 7.42 (d, J = 5.3 Hz, 1H), 7.28 (d, J = 8.3
Hz, 2H), 7.15 (d, J = 9.1 Hz, 1H), 6.63 (s, 1H), 4.44−4.29 (m, 1H),
3.78 (s, 3H), 2.32 (s, 3H), 2.10−2.06 (p, 4H), 1.95 (s, 4H); 13C
NMR (101 MHz, CD3OD): δ 176.8, 159.1, 148.4, 145.6, 144.3,
138.6, 135.6, 129.2, 127.6, 124.6, 123.3, 122.8, 122.3, 122.1, 110.9,
107.5, 56.9, 54.9, 52.8, 22.5, 21.5, 20.2; HRMS m/z: calcd for
C26H27BrN3O3S [M + H]
+, 540.0951; found, 540.0934 (Δ = 3.2
ppm).
4-({3-[4-Bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-2-yl]-4-
methoxyphenyl}methyl)morpholine (6d). Prepared according to
method B. Purification by flash chromatography (5% methanol−
dichloromethane) afforded 6d as yellow oil (270 mg, 80%); 1H NMR
(400 MHz, CD3OD): δ 8.03 (m, 3H), 7.71 (d, J = 7.9 Hz, 1H), 7.52
(d, J = 8.4 Hz, 1H), 7.31 (d, J = 4.8 Hz, 1H), 7.23−7.18 (m, 3H),
6.96 (s, 1H), 4.36 (s, 2H), 4.04 (s, 3H), 3.34 (t, J = 6.2 Hz, 4H), 2.08
(t, J = 6.2 Hz, 4H), 1.99 (s, 3H); 13C NMR (101 MHz, CD3OD): δ
157.5, 147.9, 142.5, 140.4, 136.2, 131.8, 130.4, 128.5, 125.6, 124.3,
123.6, 122.4, 120.1, 118.9, 112.2, 99.4, 62.9, 57.2, 55.2, 53.2, 22.5;
HRMS m/z: calcd for C26H27BrN3O4S [M + H]
+, 556.0900; found,
556.0902 (Δ = −0.2 ppm).
N-(3-(4-Bromo-1H-pyrrolo[2,3-b]pyridin-2-yl)-4-methoxybenzyl)-
N-ethylethanamine (7a). Prepared according to method C.
Purification by flash chromatography (10% methanol−dichloro-
methane) afforded 7a as colorless oil (560 mg, 79%); 1H NMR
(400 MHz, CD3OD): δ 8.00 (d, J = 5.3 Hz, 1H), 7.83 (d, J = 2.3 Hz,
1H), 7.36 (dd, J = 8.5, 2.2 Hz, 1H), 7.29 (d, J = 5.3 Hz, 1H), 7.13 (d,
J = 8.5 Hz, 1H), 6.91 (s, 1H), 4.00 (s, 3H), 3.75 (s, 2H), 3.31 (p, J =
1.6 Hz, 1H), 2.71 (q, J = 7.2 Hz, 4H), 1.15 (t, J = 7.2 Hz, 6H); 13C
NMR (101 MHz, CD3OD): δ 156.3, 147.9, 142.1, 136.9, 131.2,
129.7, 124.11, 122.5, 119.4, 118.8, 111.6, 98.8, 56.1, 54.9, 9.4; HRMS
m/z: calcd for C19H22BrN3O [M + H]
+, 387.0946; found, 388.1008
(Δ = 2.7 ppm).
1 - [ ( 3 - { 4 - B r omo -1H -p y r r o l o [ 2 , 3 - b ] p y r i d i n - 2 - y l } - 4 -
methoxyphenyl)methyl]dimethylamine (7b). Prepared according to
method C. Purification by flash chromatography (10% methanol−
dichloromethane) afforded 7b as colorless oil (280 mg, 92%); 1H
NMR (400 MHz, CD3OD): δ 7.91 (d, J = 5.3 Hz, 1H), 7.70 (d, J =
2.2 Hz, 1H), 7.23 (dd, J = 8.4, 2.2 Hz, 1H), 7.20 (d, J = 5.3 Hz, 1H),
7.04 (d, J = 8.5 Hz, 1H), 6.82 (s, 1H), 3.91 (s, 3H), 3.44 (s, 2H), 2.21
(s, 6H); 13C NMR (101 MHz, CD3OD): δ 156.3, 147.9, 142.1, 137.0,
131.0, 129.7, 129.5, 124.1, 122.6, 119.3, 118.8, 111.5, 98.8, 62.6, 54.9,
43.6; HRMS m/z: calcd for C17H19BrN3OS [M + H]
+, 360.0706;
found, 360.0701 (Δ = 1.4 ppm).
1 - [ ( 3 - { 4 - B r omo -1H -p y r r o l o [ 2 , 3 - b ] p y r i d i n - 2 - y l } - 4 -
methoxyphenyl)methyl]pyrrolidine (7c). Prepared according to
method C. Purification by flash chromatography (10% methanol−
dichloromethane) afforded 7c as yellow oil (165 mg, 77%); 1H NMR
(400 MHz, CD3OD): δ 7.88 (d, J = 5.2 Hz, 1H), 7.84 (d, J = 2.3 Hz,
1H), 7.36 (dd, J = 8.5, 2.3 Hz, 1H), 7.16 (dd, J = 8.5, 3.4 Hz, 1H),
7.04 (d, J = 8.6 Hz, 1H), 6.81 (s, 1H), 4.06 (s, 2H), 3.89 (s, 3H), 3.04
(t, J = 6.8 Hz, 4H), 1.91 (p, J = 3.2 Hz, 4H); 13C NMR (101 MHz,
CD3OD): δ 157.0, 148.0, 142.4, 136.5, 131.3, 130.0, 126.4, 124.2,
122.4, 119.9, 118.9, 112.0, 99.1, 58.1, 55.1, 53.4, 22.6; HRMS m/z:
calcd for C19H21BrN3O [M + H]
+, 386.0900; found, 386.0903 (Δ =
0.8 ppm).
4 - [ ( 3 - { 4 - B r omo -1H -p y r r o l o [ 2 , 3 - b ] p y r i d i n - 2 - y l } - 4 -
methoxyphenyl)methyl]morpholine (7d). Prepared according to
method C. Purification by flash chromatography (10% methanol−
dichloromethane) afforded 7d as yellow oil (269 mg, 80%); 1H NMR
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(400 MHz, DMSO-d6): δ 12.18 (s, 1H), 8.08 (d, J = 5.1 Hz, 1H),
7.80 (d, J = 2.0 Hz, 1H), 7.65−7.60 (m, 2H), 7.58−7.55 (m, 1H),
7.33 (d, J = 5.1 Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H), 7.15 (d, J = 8.5 Hz,
1H), 6.89 (d, J = 2.2 Hz, 1H), 3.94 (s, 3H), 3.58 (t, 4H), 3.47 (s,
2H), 2.38 (t, 4H); 13C NMR (101 MHz, DMSO-d6): δ 156.2, 149.1,
143.5, 136.8, 132.5, 130.9, 129.7, 129.2, 123.4, 122.1, 119.4, 119.1,
112.4, 100.2, 66.7, 62.3, 56.2, 53.6; HRMS m/z: calcd for
C19H21BrN3O2 [M + H]
+, 402.0812; found, 402.0810 (Δ = 0.5 ppm).
4-(2-(5-((Diethylamino)methyl)-2-methoxyphenyl)-1H-pyrrolo-
[2,3-b]pyridin-4-yl)-2-isopropylbenzoic Acid, 1. Prepared according
to method D. Purification by preparative HPLC 10−95% MeCN/
H2O to give 1 in a (85 mg, 68%);
1H NMR (400 MHz, CD3OD): δ
8.39 (d, J = 5.7 Hz, 1H), 8.01 (d, J = 2.2 Hz, 1H), 7.97 (d, J = 8.0 Hz,
1H), 7.91 (d, J = 1.8 Hz, 1H), 7.74 (dd, J = 8.0, 1.8 Hz, 1H), 7.58
(dd, J = 8.6, 2.3 Hz, 1H), 7.52 (d, J = 5.8 Hz, 1H), 7.32 (d, J = 8.6 Hz,
1H), 7.31 (s, 1H), 4.37 (s, 2H), 4.07 (s, 3H), 3.94 (p, J = 6.9 Hz,
1H), 3.25 (dq, J = 14.2, 7.1 Hz, 4H), 1.39−1.34 (m, 12H); 13C NMR
(101 MHz, CD3OD): δ 169.8, 157.9, 150.1, 145.6, 143.9, 140.0,
137.8, 136.8, 132.9, 131.8, 131.0, 130.3, 126.4, 125.6, 122.1, 121.8,
119.6, 114.9, 112.5, 100.3, 55.3, 55.2, 29.4, 23.0, 7.6; HRMS m/z:
calcd for C29H33N3O3 [M + H]
+, 471.2522; found, 472.2576 (Δ = 2.1
ppm).
4-(2-{5-[(Dimethylamino)methyl]-2-methoxyphenyl}-1H-pyrrolo-
[2,3-b]pyridin-4-yl)-2-(propan-2-yl)benzoic Acid (8a). Prepared
according to method D. Purification by preparative HPLC 10−95%
MeCN/H2O to give 8a in a (11 mg, 29%);
1H NMR (400 MHz,
CD3OD): δ 8.27 (d, J = 5.4 Hz, 1H), 7.89 (d, J = 2.3 Hz, 1H), 7.87
(d, J = 8.1 Hz, 1H), 7.79 (d, J = 1.7 Hz, 1H), 7.63 (dd, J = 8.0, 1.8 Hz,
1H), 7.44 (dd, J = 8.6, 2.3 Hz, 2H), 7.32 (d, J = 5.5 Hz, 1H), 7.23 (d,
J = 8.6 Hz, 1H), 7.13 (s, 1H), 4.23 (s, 2H), 3.97 (s, 3H), 3.89−3.81
(m, 1H), 2.79 (s, 6H), 1.27 (d, J = 6.9 Hz, 6H); 13C NMR (101
MHz, CD3OD): δ 169.9, 158.1, 150.2, 146.7, 142.6, 139.6, 138.4,
135.1, 133.2, 132.2, 131.1, 130.4, 126.5, 125.7, 122.3, 120.4, 119.2,
115.0, 112.5, 100.5, 60.1, 55.3, 41.4, 29.5, 23.0; HRMS m/z: calcd for
C27H29N3O3 [M + H]
+, 470.2438; found, 470.2433 (Δ = 1.1 ppm).
4-(2-{2-Methoxy-5-[(pyrrolidin-1-yl)methyl]phenyl}-1H-pyrrolo-
[2,3-b]pyridin-4-yl)-2-(propan-2-yl)benzoic Acid (8b). Prepared
according to method D. Purification by preparative HPLC 10−95%
MeCN/H2O to give 8b in a (27 mg, 37%);
1H NMR (400 MHz,
CD3OD): δ 8.27 (br s, 1H), 7.90 (s, 1H), 7.86 (d, J = 8.0 Hz, 1H),
7.79 (s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.46 (d, J = 8.6 Hz, 1H), 7.36
(s, 1H), 7.21−7.15 (m, 2H), 4.29 (s, 2H), 3.96 (s, 3H), 3.85−3.81
(m, 1H), 3.42 (br s, 2H), 3.14 (br s, 2H), 2.08 (br s, 2H), 1.93 (br s,
2H), 1.26 (d, J = 6.8 Hz, 6H); 13C NMR (101 MHz, CD3OD): δ
169.9, 157.9, 150.1, 144.5, 140.5, 137.4, 132.1, 131.5, 130.4, 130.3,
126.3, 125.5, 123.4, 119.9, 112.4, 100.0, 57.2, 55.2, 53.3, 29.4, 23.0,
22.4; HRMS m/z: calcd for C29H32N3O3 [M + H]
+, 470.2438; found,
470.2433 (Δ = 1.1 ppm).
4-(2-{2-Methoxy-5-[(morpholin-4-yl)methyl]phenyl}-1H-pyrrolo-
[2,3-b]pyridin-4-yl)-2-(propan-2-yl)benzoic Acid (8c). Prepared
according to method D. Purification by preparative HPLC 10−95%
MeCN/H2O to give 8c in a (34 mg, 60%);
1H NMR (400 MHz,
DMSO-d6): δ 8.43 (d, J = 5.8 Hz, 1H), 8.04 (d, J = 2.3 Hz, 1H), 8.00
(d, J = 8.0 Hz, 1H), 7.93 (d, J = 1.8 Hz, 1H), 7.78 (dd, J = 8.0, 1.8 Hz,
1H), 7.61 (dd, J = 8.6, 2.2 Hz, 1H), 7.56 (d, J = 5.7 Hz, 1H), 7.36 (d,
J = 8.5 Hz, 1H), 7.32 (s, 1H), 4.41 (s, 2H), 4.10 (s, 3H), 4.07 (s, 2H),
3.98−3.93 (m, 1H), 3.76 (s, 2H), 3.44 (s, 2H), 3.26 (s, 2H), 1.39 (d,
J = 6.9 Hz, 6H); 13C NMR (101 MHz DMSO-d6): δ 170.3, 169.7,
149.6, 147.1, 136.0, 133.0, 133.0, 132.2, 132.1, 131.6, 131.3, 130.6,
128.3, 126.5, 125.9, 121.7, 120.6, 112.9, 100.5, 63.8, 59.4, 56.4, 51.2,
49.1, 29.4, 24.4, 24.3; HRMS m/z: calcd for C29H32N3O4 [M + H]
+,
486.2387; found, 486.2384 (Δ = 0.8 ppm).
Ethyl 4-(2-(5-((Diethylamino)methyl)-2-methoxyphenyl)-1H-
pyrrolo[2,3-b]pyridin-4-yl)-2-isopropylbenzoate (9). Purification by
preparative HPLC 10−95% MeCN/H2O to give 9 in a (36 mg, 98%);
1H NMR (400 MHz, CD3OD): δ 8.39 (d, J = 5.6 Hz, 1H), 8.01 (d, J
= 2.2 Hz, 1H), 7.92 (d, J = 8.2 Hz, 2H), 7.77−7.72 (m, 1H), 7.57
(dd, J = 8.6, 2.2 Hz, 1H), 7.49 (d, J = 5.7 Hz, 1H), 7.33 (d, J = 8.6 Hz,
1H), 7.28 (s, 1H), 4.42 (q, J = 7.1 Hz, 2H), 4.37 (s, 2H), 4.07 (s,
3H), 3.82 (p, J = 6.9 Hz, 1H), 3.25 (p, J = 7.4 Hz, 4H), 1.50−1.29
(m, 16H); 13C NMR (101 MHz, CD3OD): δ 168.1, 157.9, 149.9,
140.7, 138.8, 137.2, 132.6, 131.1, 130.9, 130.1, 126.4, 125.6, 122.0,
120.1, 114.9, 112.5, 99.9, 60.9, 55.3, 29.6, 22.9, 13.2, 7.7; HRMS m/z:
calcd for C31H37N3O3 [M + H]
+, 499.2835; found, 500.2913 (Δ = 4.1
ppm).
3-[4-Bromo-1-(4-methylbenzenesulfonyl)-1H-pyrrolo[2,3-b]-
pyridin-2-yl]-4-methoxybenzonitrile (10). Prepared according to
method B. Purification by flash chromatography (50% ethyl
acetate−PET ether) afforded 10 as yellow oil (586 mg, 87%; 1H
NMR (400 MHz, DMSO-d6): δ 8.23 (d, J = 5.2 Hz, 1H), 8.03−7.99
(m, 2H), 7.80 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 5.2 Hz, 1H), 7.41−
7.37 (m, 2H), 7.34−7.29 (m, 2H), 6.81 (s, 1H), 3.84 (s, 3H), 2.34 (s,
3H); 13C NMR (101 MHz, DMSO- d6): δ 161.8, 148.3, 145.9, 145.7,
143.5, 137.1, 136.4, 135.5, 134.8, 130.2, 128.2, 125.0, 123.0, 119.3,
112.4, 109.5, 108.3, 103.1, 56.6, 21.6; HRMS m/z: calcd for
C22H16BrN3NaO3S [M + Na]
+, 503.9988; found, 503.9973 (Δ =
3.0 ppm).
3-{4-Bromo-1H-pyrrolo[2,3-b]pyridin-2-yl}-4-methoxybenzoni-
trile (11). Prepared according to method C. Purification by flash
chromatography (10% methanol−dichloromethane) afforded 11 as
yellow oil (327 mg, 59%); 1H NMR (400 MHz, DMSO-d6): δ 12.24
(s, 1H), 8.29 (d, J = 2.1 Hz, 1H), 8.06 (d, J = 5.1 Hz, 1H), 7.81 (dd, J
= 8.7, 2.1 Hz, 1H), 7.33−7.29 (m, 2H), 6.96 (s, 1H), 3.98 (s, 3H);
13C NMR (101 MHz, DMSO-d6): δ 207.0, 160.3, 149.1, 144.4, 134.3,
132.5, 124.1, 121.1, 119.4, 119.3, 113.7, 103.8, 101.8, 56.9, 31.2;
HRMS m/z: calcd for C15H11BrN3O [M + H]
+, 328.0080; found,
328.0076 (Δ = 1.1 ppm).
4-{2-[5-(Aminomethyl)-2-methoxyphenyl]-1H-pyrrolo[2,3-b]-
pyridin-4-yl}-2-(propan-2-yl)benzoic Acid (12). Prepared according
to method D. The filtrate residue was dissolved in methanol (10 mL),
CoCl2·6H2O (3 equiv) was then added before cooling to 0 °C.
NaBH4 (10 equiv) was slowly added to the reaction, and the mixture
was allowed to stir at room temperature for further 1 h before
filtration through Celite and purification by preparative HPLC 10−
95% MeCN/H2O to give 13 (26 mg, 60%);
1H NMR (400 MHz,
DMSO-d6): δ 12.01 (s, 1H), 8.30 (d, J = 5.0 Hz, 1H), 8.17 (br s, 2H),
7.94 (d, J = 2.3 Hz, 1H), 7.82−7.80 (m, 2H), 7.62 (dd, J = 8.0, 1.8
Hz, 1H), 7.41 (dd, J = 8.6, 2.2 Hz, 1H), 7.24 (d, J = 5.0 Hz, 1H), 7.18
(d, J = 8.6 Hz, 1H), 7.09 (s, 1H), 3.98 (q, J = 5.6 Hz, 2H), 3.89 (s,
3H), 3.83−3.76 (m, 1H), 1.25 (d, J = 6.9 Hz, 6H).; 13C NMR (101
MHz, DMSO-d6): δ 169.7, 157.0, 149.6, 149.2, 142.9, 141.4, 140.4,
136.6, 131.4, 130.6, 130.6, 129.7, 126.7, 126.6, 125.9, 120.1, 119.0,
115.2, 112.7, 100.0, 56.3, 42.4, 29.4, 24.3; HRMS m/z: calcd for
C25H26N3O3 [M + H]
+, 416.1969; found, 416.1968 (Δ = 0.2 ppm).
4-Bromo-2-(2-methoxyphenyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine
(13). Prepared according to method A. Purification by flash
chromatography (50% ethyl acetate−PET ether) afforded 14 as
colorless oil (960 mg, 32%); 1H NMR (400 MHz, CDCl3): δ 8.14 (d,
J = 5.3 Hz, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.41 (td, J = 8.2, 1.7 Hz,
1H), 7.29−7.24 (m, 2H), 7.12 (d, J = 8.1 Hz, 2H), 6.99 (t, J = 7.5 Hz,
1H), 6.91 (d, J = 8.2 Hz, 1H), 6.45 (s, 1H), 3.73 (s, 3H), 2.27 (s,
3H); 13C NMR (101 MHz, CDCl3): δ 158.3, 148.7, 144.8, 144.4,
139.4, 136.1, 131.1, 130.9, 129.2, 128.2, 124.8, 123.5, 122.1, 121.8,
120.0, 110.4, 107.3, 55.5, 21.6; HRMS m/z: calcd for
C21H17BrN2NaO3S [M + Na]
+, 479.0035; found, 479.0035 (Δ =
0.0 ppm).
4-Bromo-2-(2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine (14).
Prepared according to method C. Purification by flash chromatog-
raphy (10% methanol−dichloromethane) afforded 15 as colorless oil
(300 mg 80%); 1H NMR (400 MHz, CDCl3): δ 10.38 (s, 1H), 8.09
(d, J = 5.2 Hz, 1H), 7.92 (dd, J = 7.8, 1.6 Hz, 1H), 7.41−7.34 (m,
1H), 7.30−7.25 (m, 2H), 7.14−7.07 (m, 2H), 6.89 (s, 1H), 4.04 (s,
3H); 13C NMR (101 MHz, CDCl3): δ 156.1, 148.1, 143.0, 137.0,
129.9, 128.4, 124.3, 122.2, 121.6, 119.4, 119.3, 112.0, 97.8, 55.9;
HRMS m/z: calcd for C14H12BrN2O [M + H]
+, 303.0128; found,
303.0122 (Δ = 1.8 ppm).
4-[2-(2-Methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-2-(prop-
an-2-yl)benzoic Acid (15). Prepared according to method D.
Purification by preparative HPLC 10−95% MeCN/H2O to give 16
in a (30 mg, 59%); 1H NMR (400 MHz, DMSO-d6): δ 12.05 (s, 1H),
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8.32 (d, J = 5.0 Hz, 1H), 7.92 (dd, J = 7.8, 1.7 Hz, 1H), 7.90 (d, J =
1.8 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.68 (dd, J = 8.1, 1.8 Hz, 1H),
7.38 (ddd, J = 8.7, 7.4, 1.7 Hz, 1H), 7.27 (d, J = 5.0 Hz, 1H), 7.20−
7.18 (m, 2H), 7.08 (td, J = 7.6, 1.0 Hz, 1H), 3.92 (s, 3H), 3.90−3.83
(m, 1H), 1.32 (d, J = 6.9 Hz, 6H); 13C NMR (101 MHz, DMSO-d6):
δ 169.7, 157.1, 149.9, 149.6, 141.7, 136.5, 131.1, 130.7, 129.9, 126.5,
125.9, 121.2, 100.3, 45.4, 29.4; HRMS m/z: calcd for C24H23N2O3 [M
+ H]+, 387.17034; found, 387.1710 (Δ = −1.7 ppm).
3-(4-Bromo-1-tosyl -1H-pyrrolo[2 ,3-b]pyr idin-2-y l ) -4-
(methoxymethoxy)benzaldehyde (16). Prepared according to
method A. Purification by flash chromatography (50% ethyl
acetate−PET ether) afforded 17 as colorless oil (850 mg, 77%); 1H
NMR (400 MHz, CDCl3): δ 9.92 (s, 1H), 8.16 (d, J = 5.3 Hz, 1H),
7.92 (dd, J = 8.5, 2.1 Hz, 1H), 7.84 (d, J = 2.1 Hz, 1H), 7.69 (d, J =
8.4 Hz, 2H), 7.35 (d, J = 8.5 Hz, 1H), 7.29 (d, J = 5.3 Hz, 1H), 7.12
(d, J = 8.1 Hz, 3H), 6.53 (s, 1H), 5.26−5.22 (m, 2H), 3.46 (s, 3H),
2.27 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 190.6, 161.7, 148.6,
145.2, 144.9, 137.7, 135.5, 134.4, 131.0, 130.0, 129.4, 128.0, 125.1,
123.6, 122.3, 113.9, 108.0, 95.1, 56.9, 21.6; HRMS m/z: calcd for
C23H19BrN2NaO5S [M + Na]




(17). Prepared according to method B. Purification by flash
chromatography (5% methanol−dichloromethane) afforded 18 as
colorless oil (672 mg, 87%); 1H NMR (400 MHz, CD3OD): δ 8.16
(d, J = 5.3 Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 7.9 Hz, 2H),
7.50 (d, J = 5.3 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 8.2 Hz,
2H), 6.68 (s, 1H), 5.18 (br s, 1H), 5.28 (br s, 1H), 4.20 (d, J = 5.4
Hz, 2H), 3.43 (s, 3H), 3.10 (q, J = 7.1 Hz, 4H), 2.37 (s, 3H), 1.33 (t,
J = 7.2 Hz, 6H); 13C NMR (101 MHz, CD3OD): δ 156.7, 148.4,
145.7, 144.3, 138.7, 135.5, 133.1, 132.9, 129.2, 127.6, 124.7, 123.3,
122.8, 122.4, 114.1, 107.5, 94.7, 55.4, 55.4, 46.2, 20.1, 8.4; HRMS m/
z: calcd for C27H31BrN3O4S [M + H]
+, 572.1213; found, 572.1208 (Δ
= 0.9 ppm).
[ ( 3 - { 4 - B r omo - 1H - p y r r o l o [ 2 , 3 - b ] p y r i d i n - 2 - y l } - 4 -
(methoxymethoxy)phenyl)methyl]diethylamine (18). Prepared ac-
cording to method C. Purification by flash chromatography (10%
methanol−dichloromethane) afforded 19 as yellow oil (420 mg,
69%); 1H NMR (400 MHz, CD3OD): δ 8.03 (d, J = 5.2 Hz, 1H),
7.84 (d, J = 2.1 Hz, 1H), 7.34 (dd, J = 8.5, 2.1 Hz, 1H), 7.31−7.28
(m, 2H), 6.96 (s, 1H), 5.39 (s, 2H), 4.88 (s, 3H), 3.73 (s, 2H), 3.50
(s, 3H), 2.70 (q, J = 7.2 Hz, 4H), 1.15 (t, J = 7.2 Hz, 6H); 13C NMR
(101 MHz, CD3OD): δ 153.9, 148.0, 142.3, 136.7, 130.9, 130.5,
129.7, 124.2, 122.6, 120.4, 118.9, 115.2, 99.3, 94.7, 56.1, 55.4, 46.1,
9.5; HRMS m/z: calcd for C21H25BrN2O2 [M + H]
+, 418.1113;
found, 418.1112 (Δ = −0.2 ppm).
4-[2-(2-Methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-2-(prop-
an-2-yl)benzoic Acid (19). Prepared according to method D. The
filter residue was then stirred in a mixture of acetonitrile/HCl (3:1)
for 30 min before filtering through Celite and purification by
preparative HPLC 10−95% MeCN/H2O to give 21 in a (72 mg,
70%); 1H NMR (400 MHz, CD3OD): δ 8.30 (d, J = 5.3 Hz, 1H),
7.92 (d, J = 2.2 Hz, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.84 (d, J = 1.6 Hz,
1H), 7.68 (dd, J = 8.1, 1.7 Hz, 1H), 7.46 (d, J = 5.7 Hz, 1H), 7.3−
7.31 (m, 2H), 7.04 (d, J = 8.4 Hz, 1H), 4.24 (s, 2H), 3.85 (sept, J =
6.9 Hz, 1H), 3.19−3.12 (m, 4H), 1.30−1.27 (m, 12H); 13C NMR
(101 MHz, CD3OD): δ 169.8, 156.5, 150.2, 139.7, 138.9, 135.4,
132.7, 132.1, 130.8, 130.4, 126.6, 125.7, 121.0, 117.4, 117.1, 115.0,
99.7, 55.4, 46.4, 29.5, 23.0; HRMS m/z: calcd for C28H32N3O3 [M +
H]+, 458.2438; found, 458.2430 (Δ = 1.8 ppm).
3-(4-Bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-2-yl)benzaldehyde
(20). Prepared according to method A. Purification by flash
chromatography (50% ethyl acetate−PET ether) afforded 22 as
colorless oil (500 mg, 76%); 1H NMR (400 MHz, CDCl3): δ 10.04
(s, 1H), 8.23 (d, J = 5.2 Hz, 1H), 7.96 (t, J = 1.8 Hz, 1H), 7.93 (d, J =
7.7 Hz, 1H), 7.79 (d, J = 7.7 Hz, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.59
(t, J = 7.7 Hz, 1H), 7.33 (d, J = 5.3 Hz, 1H), 7.14 (d, J = 8.3 Hz, 2H),
6.56 (s, 1H), 2.29 (s, 3H); 13C NMR (101 MHz, CDCl3): δ 191.8,
149.5, 145.5, 145.2, 141.0, 136.0, 135.9, 135.2, 133.3, 130.6, 130.3,
129.6, 128.5, 127.9, 125.3, 123.6, 122.9, 109.1, 21.7; HRMS m/z:
calcd for C21H15BrN2NaO3S [M + Na]
+, 476.9879; found, 476.9884
(Δ = −1.0 ppm).
({3-[4-Bromo-1-(4-methylbenzenesulfonyl)-1H-pyrrolo[2,3-b]-
pyridin-2-yl]-4-(methoxymethoxy)phenyl}methyl)diethylamine
(21). Prepared according to method B. Purification by flash
chromatography (5% methanol−dichloromethane) afforded 23 as
colorless oil (154 mg, 83%); 1H NMR (400 MHz, CD3OD): δ 8.22
(d, J = 5.3 Hz, 1H), 7.87 (d, J = 1.9 Hz, 1H), 7.75−7.70 (m, 2H),
7.68 (d, J = 7.4 Hz, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 5.3 Hz,
1H), 7.29 (d, J = 8.4 Hz, 2H), 6.79 (s, 1H), 4.50 (s, 2H), 3.35−3.30
(m, 4H), 2.35 (s, 3H), 1.42 (t, J = 7.3 Hz, 6H); 13C NMR (101 MHz,
CD3OD): δ 156.7, 148.4, 145.7, 144.3, 138.7, 135.5, 133.1, 132.9,
129.2, 127.6, 124.7, 123.3, 122.8, 122.4, 114.1, 107.5, 94.7, 55.4, 55.4,
46.2, 20.1, 8.4; HRMS m/z: calcd for C25H27BrN3O2S [M + H]
+,
512.1002; found, 512.1013 (Δ = −2.3 ppm).
[(3-{4-Bromo-1H-pyrrolo[2,3-b]pyridin-2-yl}phenyl)methyl]-
diethylamine (22). Prepared according to method C. Purification by
flash chromatography (10% methanol−dichloromethane) afforded 24
as colorless oil (95 mg, 89%); 1H NMR (400 MHz, CD3OD): δ 7.92
(d, J = 5.3 Hz, 1H), 7.78 (s, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.37 (t, J =
7.6 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 7.20 (d, J = 5.3 Hz, 1H), 6.76
(s, 1H), 3.70 (s, 2H), 2.62 (q, J = 7.2 Hz, 4H), 1.06 (t, J = 7.1 Hz,
6H); 13C NMR (101 MHz, CD3OD): δ 148.9, 142.4, 139.7, 131.5,
129.7, 128.9, 126.8, 124.7, 124.2, 123.2, 118.9, 96.9, 56.8, 46.3, 9.6;
HRMS m/z: calcd for C18H21BrN3 [M + H]
+, 358.0913; found,
358.0907 (Δ = 1.7 ppm).
4-(2-{3-[(Diethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-
4-yl)-2-(propan-2-yl)benzoic Acid (23). Prepared according to
method D. Purification by preparative HPLC 10−95% MeCN/H2O
to give 25 in a (30 mg, 70%); 1H NMR (400 MHz, CD3OD): δ 8.25
(s, 1H), 7.94 (s, 1H), 7.91 (d, J = 6.9 Hz, 1H), 7.85 (d, J = 8.0 Hz,
1H), 7.73 (s, 1H), 7.62 (s, 2H), 7.53 (s, 2H), 7.45 (d, J = 7.7 Hz,
1H), 7.28 (d, J = 5.2 Hz, 1H), 7.04 (s, 1H), 4.32 (s, 2H), 3.83 (sept, J
= 13.9, 6.9 Hz, 1H), 3.16 (br s, 4H), 1.27 (q, J = 7.2 Hz, 12H); 13C
NMR (101 MHz, CD3OD): δ 170.0, 150.1, 132.3, 130.8, 130.6,
130.3, 129.9, 128.1, 127.0, 126.2, 125.5, 115.1, 111.9, 97.8, 55.7, 46.7,
29.4, 23.0, 7.6; HRMS m/z: calcd for C28H32N3O2 [M + H]
+,
442.2489; found, 442.2476 (Δ = 3.0 ppm).
3-(4-Bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-2-methoxy-
benzaldehyde (24). Prepared according to method A. Purification by
flash chromatography (50% ethyl acetate−PET ether) afforded 26 as
colorless oil (990 mg, 72%); 1H NMR (400 MHz, CDCl3): δ 10.49
(s, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.07−7.90 (m, 3H), 7.59 (dd, J =
7.4, 1.8 Hz, 1H), 7.41 (d, J = 5.3 Hz, 1H), 7.37−7.30 (m, 1H), 7.25
(d, J = 6.7 Hz, 2H), 6.66 (s, 1H), 3.75 (s, 3H), 2.38 (s, 3H); 13C
NMR (101 MHz, CDCl3): δ 189.6, 162.0, 148.7, 145.4, 145.0, 137.1,
137.1, 135.6, 130.2, 129.4, 129.0, 128.6, 127.3, 125.2, 123.7, 123.1,
122.5, 108.1, 63.6, 21.7; HRMS m/z: calcd for C22H17BrN2O4SNa [M
+ Na]+, 507.9990; found, 508.0068 (Δ = 0.2 ppm).
N-(3-(4-Bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-2-methox-
ybenzyl)-N-ethylethanamine (25). Prepared according to method B.
Purification by flash chromatography (50% ethyl acetate−PET ether)
afforded 27 as yellow oil (765 mg, 81%; 1H NMR (400 MHz,
CD3OD): δ 8.18 (d, J = 5.3 Hz, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.69
(dd, J = 7.7, 1.7 Hz, 1H), 7.63 (dd, J = 7.6, 1.7 Hz, 1H), 7.51 (d, J =
5.3 Hz, 1H), 7.41 (t, J = 7.7 Hz, 1H), 7.33−7.27 (m, 2H), 6.85 (s,
1H), 4.56 (d, J = 13.3 Hz, 1H), 4.28 (d, J = 13.3 Hz, 1H), 3.58 (s,
3H), 2.35 (s, 3H), 1.39 (t, J = 7.3 Hz, 6H); 13C NMR (101 MHz,
CD3OD): δ 178.1, 158.6, 148.6, 145.9, 144.8, 138.4, 135.2, 133.7,
132.8, 129.2, 127.8, 126.4, 124.9, 124.2, 124.1, 123.2, 122.6, 108.0,
60.3, 50.2, 22.4, 20.2, 8.1; HRMS m/z: calcd for C26H28BrN3O3S [M
+ H]+, 541.1035; found, 542.1095 (Δ = 3.6 ppm).
N-(3-(4-Bromo-1H-pyrrolo[2,3-b]pyridin-2-yl)-2-methoxybenzyl)-
N-Ethylethanamine (26). Prepared according to method C.
Purification by flash chromatography (5% methanol−dichloro-
methane) afforded 28 as yellow oil (630 mg, 85%); 1H NMR (400
MHz, CD3OD): δ 8.12 (d, J = 5.4 Hz, 1H), 7.92 (dd, J = 7.8, 1.7 Hz,
1H), 7.59 (dd, J = 7.6, 1.7 Hz, 1H), 7.46−7.37 (m, 2H), 7.03 (s, 1H),
4.43 (s, 2H), 3.69 (s, 3H), 3.32−3.28 (m, 4H), 1.43 (t, J = 7.3 Hz,
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6H); 13C NMR (101 MHz, CD3OD): δ 157.0, 147.6, 142.1, 135.7,
132.8, 131.9, 125.6, 125.4, 125.3, 124.5, 123.2, 119.2, 100.5, 60.6,
50.9, 7.7; HRMS m/z: calcd for C19H22BrN3O [M + H]
+, 387.0946;
found, 388.1008 (Δ = 2.7 ppm).
4-(2-(3-((Diethylamino)methyl)-2-methoxyphenyl)-1H-pyrrolo-
[2,3-b]pyridin-4-yl)-2-isopropylbenzoic Acid (27). Prepared accord-
ing to method D. Purification by preparative HPLC 10−95% MeCN/
H2O to give 29 in a (30 mg, 74%);
1H NMR (400 MHz, CD3OD): δ
8.41 (s, 1H), 7.98−7.92 (m, 2H), 7.89 (d, J = 1.7 Hz, 1H), 7.73 (dd, J
= 8.1, 1.7 Hz, 1H), 7.58 (dd, J = 7.6, 1.6 Hz, 1H), 7.47−7.43 (m, 1H),
7.41 (d, J = 7.7 Hz, 1H), 7.23 (s, 1H), 4.43 (s, 2H), 3.94 (p, J = 6.8
Hz, 1H), 3.72 (s, 3H), 3.31−3.25 (m, 5H), 1.42 (t, J = 7.3 Hz, 6H),
1.36 (d, J = 6.9 Hz, 6H); 13C NMR (101 MHz, CD3OD): δ 169.9,
157.1, 150.1, 140.6, 136.3, 132.8, 131.9, 131.4, 130.3, 126.3, 125.5,
125.4, 124.6, 100.5, 60.7, 50.8, 29.4, 23.0, 7.7; HRMS m/z: calcd for
C29H33N3O3 [M + H]
+, 471.2522; found, 472.2579 (Δ = 3.4 ppm).
4-(2-(5-((Diethylamino)methyl)-2-methoxyphenyl)-1H-pyrrolo-
[2,3-b]pyridin-4-yl)-2-methylbenzoic Acid (28). Prepared according
to method D. Purification by preparative HPLC 10−95% MeCN/
H2O to give 30 in a (50 mg, 75%);
1H NMR (101 MHz, CD3OD): δ
8.27 (d, J = 5.6 Hz, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.94 (d, J = 2.3 Hz,
1H), 7.70−7.61 (m, 2H), 7.46 (dd, J = 8.6, 2.3 Hz, 1H), 7.36 (d, J =
5.6 Hz, 1H), 7.23 (d, J = 8.6 Hz, 1H), 7.16 (s, 1H), 4.27 (s, 2H), 3.99
(s, 3H), 3.15 (p, J = 7.2 Hz, 4H), 2.63 (s, 3H), 1.27 (t, J = 7.3 Hz,
6H); 13C NMR (400 MHz, CD3OD): δ 168.9, 157.8, 140.9, 140.3,
136.5, 133.0, 131.5, 131.3, 131.2, 125.9, 122.2, 119.6, 115.1, 112.5,
99.7, 55.3, 20.6, 7.6; HRMS m/z: calcd for C27H29N3O3 [M + H]
+,
443.2209; found, 444.2214 (Δ = 1.4 ppm).
4-(2-(5-((Diethylamino)methyl)-2-methoxyphenyl)-1H-pyrrolo-
[2,3-b]pyridin-4-yl)benzoic Acid (29). Prepared according to method
D. Purification by preparative HPLC 10−95% MeCN/H2O to give 31
in a (100 mg, 85%); 1H NMR (400 MHz, CD3OD): δ 8.28 (d, J = 5.5
Hz, 1H), 8.16 (d, J = 8.5 Hz, 2H), 7.95 (d, J = 2.3 Hz, 1H), 7.87 (d, J
= 8.6 Hz, 2H), 7.46 (dd, J = 8.6, 2.3 Hz, 1H), 7.38 (d, J = 5.6 Hz,
1H), 7.23 (d, J = 8.6 Hz, 1H), 7.17 (s, 1H), 4.27 (s, 2H), 3.99 (s,
3H), 3.15 (p, J = 7.3 Hz, 4H), 1.27 (t, J = 7.3 Hz, 6H); 13C NMR
(101 MHz, CD3OD): δ 168.0, 157.6, 148.6, 143.1, 142.4, 140.9,
136.3, 132.0, 130.9, 130.6, 129.9, 129.3, 128.3, 122.1, 120.8, 114.9,
112.4, 98.6, 55.5, 55.2, 7.6; HRMS m/z: calcd for C26H27N3O3 [M +
H]+, 429.2052; found, 430.2056 (Δ = 1.1 ppm).
N-Ethyl-N-(3-(4-(3-isopropyl-4-(1H-tetrazol-5-yl)phenyl)-1H-
pyrrolo[2,3-b]pyridin-2-yl)-4-methoxybenzyl)ethanamine (30). Pre-
pared according to method D. Purification by preparative HPLC 10−
95% MeCN/H2O to give 32 in a (27 mg, 62%);
1H NMR (400 MHz,
CD3OD): δ 8.39 (d, J = 5.8 Hz, 1H), 8.01 (d, J = 2.3 Hz, 1H), 7.97
(d, J = 8.0 Hz, 1H), 7.91 (d, J = 1.8 Hz, 1H), 7.74 (dd, J = 8.0, 1.9 Hz,
1H), 7.58 (dd, J = 8.6, 2.3 Hz, 1H), 7.52 (d, J = 5.8 Hz, 1H), 7.32 (d,
J = 8.7 Hz, 1H), 7.31 (s, 1H), 4.37 (s, 2H), 4.07 (s, 3H), 3.94 (p, J =
6.9 Hz, 1H), 3.25 (dd, J = 12.2, 7.0 Hz, 4H), 1.42−1.33 (m, 12H);
13C NMR (101 MHz, CD3OD): δ 169.8, 157.9, 150.1, 145.6, 143.9,
140.0, 137.8, 136.8, 132.9, 131.8, 131.0, 130.3, 126.4, 125.6, 122.1,
121.8, 119.6, 114.9, 112.5, 100.3, 55.3, 55.2, 29.4, 23.0, 7.6; HRMS
m/z: calcd for C29H33N7O [M + H]
+, 495.2747; found, 496.2829 (Δ
= 0.6 ppm).
N-Ethyl-N-(3-(4-(3-isopropylphenyl)-1H-pyrrolo[2,3-b]pyridin-2-
yl)-4-methoxybenzyl)ethanamine (31). Prepared according to
method D. Purification by preparative HPLC 10−95% MeCN/H2O
to give 33 in a (67 mg, 82%); 1H NMR (101 MHz, CD3OD): δ 8.37
(d, J = 5.9 Hz, 1H), 8.03 (d, J = 2.2 Hz, 1H), 7.75−7.68 (m, 2H),
7.61−7.54 (m, 2H), 7.50 (dd, J = 16.9, 6.8 Hz, 2H), 7.33 (d, J = 8.0
Hz, 2H), 4.37 (s, 2H), 4.08 (s, 3H), 3.25 (p, J = 7.5 Hz, 4H), 3.08 (p,
J = 6.9 Hz, 1H), 1.43−1.31 (m, 12H); 13C NMR (400 MHz,
CD3OD): δ 157.9, 149.9, 137.2, 132.8, 131.1, 128.9, 127.7, 126.5,
126.1, 122.1, 119.8, 114.9, 112.5, 100.3, 55.3, 34.1, 23.1, 7.6; HRMS
m/z: calcd for C28H33N3O [M + H]
+, 427.2624; found, 428.2624 (Δ
= 3.8 ppm).
5-(2-(5-((Diethylamino)methyl)-2-methoxyphenyl)-1H-pyrrolo-
[2,3-b]pyridin-4-yl)-2-isopropylbenzoic Acid (32). Prepared accord-
ing to method D. Purification by preparative HPLC 10−95% MeCN/
H2O to give 34 in a (55 mg, 78%);
1H NMR (400 MHz, CD3OD): δ
8.41 (d, J = 5.7 Hz, 1H), 8.26 (d, J = 2.0 Hz, 1H), 7.99 (ddd, J = 9.3,
8.0, 1.9 Hz, 2H), 7.73 (d, J = 8.2 Hz, 1H), 7.60 (dd, J = 7.6, 1.6 Hz,
1H), 7.53 (d, J = 5.7 Hz, 1H), 7.42 (t, J = 7.7 Hz, 1H), 7.36 (s, 1H),
4.43 (s, 2H), 3.92 (p, J = 6.9 Hz, 1H), 3.73 (s, 3H), 3.31−3.25 (m,
4H), 1.42 (t, J = 7.3 Hz, 6H), 1.34 (d, J = 6.9 Hz, 6H); 13C NMR
(101 MHz, CD3OD): δ 169.8, 157.0, 151.0, 145.4, 144.8, 137.8,
136.9, 134.4, 133.1, 131.9, 131.6, 131.3, 129.8, 127.2, 125.4, 124.9,
124.7, 121.6, 114.9, 100.8, 60.7, 50.9, 29.4, 22.8, 7.7; HRMS m/z:
calcd for C29H33N3O3 [M + H]
+, 471.2522; found, 472.2579 (Δ = 3.4
ppm).
Assay. P. falciparum Culture and Synchronization. P. falciparum
cultures were maintained in RPMI-1640 media (Invitrogen)
supplemented with 0.2% sodium bicarbonate, 0.5% AlbuMAX II,
2.0 mM L-glutamine (Sigma), and 10 mg/L gentamycin. For
continuous culture, the parasites were kept at 4% hematocrit in
human erythrocytes from 0 + blood donors and between 0.5 and 3%
parasitemia maintained in an incubator at 37 °C, 5% carbon dioxide
(CO2), 5% oxygen (O2), and 90% nitrogen (N2). To obtain highly
synchronous ring-stage parasites for the drug assays, cultures were
double synchronized using Percoll and sorbitol synchronization, as
previously described.35,36 First, highly segmented schizonts were
enriched by centrifugation on a 70% Percoll (GE Healthcare) cushion
gradient. The Schizont pellet was collected and washed before fresh
erythrocytes were added to a final hematocrit of 4%. The schizonts
were incubated for about 1−2 h shaking continuously to allow egress
and reinvasion of new erythrocytes. Residual schizonts were then
removed by treating the pellet with sorbitol to generate highly
synchronous 1−2 h old ring-stage parasites.
Determining the EC50 of Compound Inhibitors and Drugs
Ex Vivo. To determine the EC50 of the molecules in parasites (P.
falciparum 3D7) ex vivo, the molecules were diluted 1 in 3 from a
starting concentration of 100 μM for 12 dilution points. In total, 50
mL of freshly diluted drugs, at twice the required final concentrations,
were aliquoted into black 96-well plates. To the drug plates, 50 μL of
parasites prepared at 8% hematocrit at parasitemia (0.3−0.5%) were
added and mixed by pipetting up and down several times giving a final
culture volume of 100 μL at the required drug concentration (top
concentration of 100 μM) and 4% hematocrit. To the “no drug”
control, growth media was added, and uninfected erythrocytes were
included on the plate as blank. The outer wells were filled with media
to reduce evaporation from the experimental wells, and the plates
were incubated for 50 h (±2 h) to allow the parasites sufficient time
to reinvade before they are collected and frozen. To quantify growth
inhibition, the plates were thawed at room temperature for at least 1
h, and 100 μL of lysis buffer (20 mM Tris-HCl; 5 mM EDTA; 0.004%
saponin and triton X-100) in PBS containing Sybr Green I (1 μL in 5
mL) was added to each well and mixed by pipetting up and down
several times and incubated for 1 h in the dark with shaking. Using a
Fluoroskan/ClarioStar plate reader at excitation of 485 nm and
emission of 538 nm, plate absorbances were acquired. The data were
normalized against the controls, and graphs were generated using
GraphPad prism 8 to determine the EC50 values using the nonlinear
regression log (inhibitor) versus response (three parameter) curve.
TR-FRET to Determine the IC50 of the Inhibitors with Full-
Length PfCLK3 Recombinant Protein. The TR-FRET assays, a
high-throughput inhibition assay, as described previously,13 was used
to determine the potency of the small molecules generated against
full-length PfCLK3 recombinant protein in a kinase buffer
(containing 50 mM HEPES, 10 mM MgCl2, 2 mM DTT, 0.01%
Tween 20, and 1 mM EGTA), with the ULight-labeled peptide
substrate MBP peptide (sequence: CFFKNIVTPRTPPPSQGK).
First, in a 10 μL reaction volume, 5 μL of twice the required enzyme
concentration (50 nM) and 2.5 μL of four times the required
substrate concentration mix containing cold ATP, and the serially
diluted drugs were mixed in a black 384-plate well plate and incubated
at 37 °C for 1 h. The reaction was stopped after incubation by adding
the stopping/detection solution (containing 30 mM EDTA in 1×
Lance detection buffer and 3 nM Europium-labeled antiphospho-
specific antibody) and incubated for another hour at RT before
phosphorylation signals were measured using the ClarioStar.
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For each test compound, percent inhibition (response) which was










(maximum kinase activity blank)
was plotted against the log molar concentration of compound to
calculate the IC50 (potency) of each inhibitor molecule and plotted
using GraphPad prism software. All experiments were carried out in
triplicates, and the data presented were the standard error of the mean
(SEM) of three independent experiments run in triplicates.
PfCLK3 phosphorylation of substrate results in the Europium-
labeled antiphospho-specific antibody recognizing the phosphorylated
site on the substrate. The Europium donor fluorophore is excited at
320 or 340 nm, and energy is transferred to the ULight acceptor dye
on the substrate, which finally results in the emission of light at 665
nm. The level of ULight peptide phosphorylation correlates with the
intensity of the emission. For normalization, a no kinase and a no
inhibitor reaction wells were included, and all experiments were
conducted in triplicates. Drug dilutions, protein concentrations, and
incubation times were the same for easy comparison of results.
Microsomal Stability. Compounds were incubated at 37 °C at a
concentration of 1 μM with CD1 mouse liver microsomes (GIBCO,
Thermo Fisher Scientific) in a suspension of 50 mM potassium
phosphate buffer (pH 7.4) with a final protein concentration of 0.5
mg/mL. The reaction was started by the addition of excess NADPH
and then quenched at several time points starting from time 0, then at
3, 6, 9, 15, and 30 min addition of acetonitrile to an aliquot of the
sample. An internal standard was added to each sample before
centrifugation to remove any precipitates before monitoring loss of
parent compound by HPLC analysis using Shimadzu LC-20A
(Shimadzu, UK). Prism (Graphpad, USA) was used to fit an
exponential decay for substrate depletion and subsequently rate
constant (k) from the peak area of the parent compound to the
internal standard at each time point. The rate of intrinsic clearance
(CLint) was then calculated according to the methods of Obach using
the equation37
= × ×k VCL (mL/min /g liver) microsomal protein yieldint
where V is the incubation volume (volume/mg protein), and
microsomal protein yield is assumed to be 52.5 mg protein/g liver
with verapamil used as a positive control.
Distribution Coefficient (log D7.4). Distribution coefficient (log
D7.4) was estimated by correlation of the compounds’ chromato-
graphic retention properties to those of 10 standard compounds with
known distribution coefficients ranging from −0.5 to 5.5 at pH 7.4. A
fast gradient HPLC methodology was used based on the method
developed by Valko ́ et al.38
Kinase Screen Method. Each enzyme is assayed in its linear
range with 0.3 μM substrate in 50 mM Tris pH 7.5, 0.1 mM EGTA,
0.01 mM DTT, and relevant Mg/ATP (5, 20, or 50 μM) for 30 min
at room temp. Assays are stopped by the addition of 3%
orthophosphoric acid and harvested onto a p81 filter paper using
the PerkinElmer unifilter harvester. Once dried, they are read on a
PerkinElmer Topcount NXT scintillation counter for 30 s/well.39
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Colmenarejo, G.; Lafuente-Monasterio, M. J.; Leon, M. L.; Godoi,
P. H. C.; Elkins, J. M.; Waters, A. P.; Jamieson, A. G.; Álvaro, E. F.;
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